Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients.

Clinical pharmacology and therapeutics - 1 Aug 2013

Rae J M

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cytochrome P-450 CYP2D6
Share to Estrogen Antagonists
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Postmenopause

Share to Tamoxifen

Source

Identifiers

PMID: 23872830
DOI: 10.1038/clpt.2013.102

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients.PMID 23872830Read ↗

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapySemantic proximity Read ↗

CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies.Semantic proximity Read ↗

Pharmacogenetics of endocrine therapy for breast cancer.Semantic proximity Read ↗

Should CYP2D6 be genotyped when treating with tamoxifen?Semantic proximity Read ↗

Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.Semantic proximity Read ↗

Should CYP2D6 be genotyped when treating with tamoxifen?Semantic proximity Read ↗

CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical RelevanceSemantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Semantic proximity Read ↗

Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Semantic proximity Read ↗

Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?Semantic proximity Read ↗

CYP2D6 testing for breast cancer patients: is there more to the story?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.